An ongoing dialogue on HIV/AIDS, infectious diseases,
January 29th, 2009
Too Many Options: What Actually Happened
We recently published a case in AIDS Clinical Care entitled “Too Many Options”, describing a patient with longstanding HIV infection, virologic failure, and resistance to NRTIs, NNRTIs, and PIs.
Fortunately, resistance and tropism testing gave him several options for a new drug regimen — including darunavir, etravirine, maraviroc, enfuvirtide, and — if one believes phenotypic NRTI susceptibility with multiple TAMs — several NRTIs.
And what did our three experts suggest? Three different regimens:
- Sharon Walmsley: darunavir/r, maraviroc, and etravirine (three drugs — not counting ritonavir)
- Tim Wilkin: darunavir/r, raltegravir, maraviroc, and tenofovir/FTC (five drugs)
- Graeme Moyle: darunavir/r, raltegravir, and maraviroc (three drugs, but different from Sharon’s selection)
Now these are smart, highly-experienced clinicians, physicians who are active in clinical research, know the literature extremely well, and actually see patients. (Funny how that last part is sometimes left out.) Each of them provided sound reasons for their (varying) choices.
And what did we do with this patient? (Or one very much like him … obviously some details changed as per HIPAA mandate.)
We offered him the chance to enroll in the clinical study ACTG 5241 (mentioned by Tim), which takes patients like this, gives them an optimal regimen — then randomizes them to receive or not to receive NRTIs.
(I don’t think it will ruin the study to mention that the “flip of the coin” gave him the “No Nukes” option.)
I sure hope we learn something from this study. While we know that regimens should contain “two (preferably three)” active agents, beyond that there’s plenty of uncertainty out there.
2 Responses to “Too Many Options: What Actually Happened”
Paul E. Sax, MD
Associate Editor
NEJM Clinician
Biography | Disclosures & Summaries
Learn more about HIV and ID Observations.
FROM NEJM — Recent Infectious Disease Articles- Pulmonary Mucormycosis February 12, 2026A 49-year-old man with acute myeloid leukemia was evaluated for prolonged neutropenic fever. On examination, there were crackles at the lung bases. CT of the chest revealed a reversed halo sign.
- Mucormycosis February 12, 2026Mucormycosis is a rapidly progressive, invasive fungal infection that causes severe disease. The latest epidemiologic data, risk factors, diagnostic strategies, and treatment approaches are reviewed.
- A Pediatrician’s Dilemma — Pushing Back against CDC Guidance in the Exam Room February 12, 2026When a mother cites the CDC as her source of dangerous misinformation about vaccines, her child’s pediatrician struggles: how hard can a doctor push back without destroying the trust built over a lifetime?
- Adenoviral Inciting Antigen and Somatic Hypermutation in VITT February 12, 2026VITT is caused by a somatic hypermutation of an anti–adenovirus pVII antibody that generates more avid binding of platelet factor 4 than of adenovirus pVII, its original target, which results in platelet activation.
- Dengue Suppression by Male Wolbachia-Infected Mosquitoes February 11, 2026In this report from Singapore, the release of wolbachia-infected, irradiated male Aedes aegypti mosquitoes resulted in a reduction in the vector population and in the risk of dengue infection.
- Pulmonary Mucormycosis February 12, 2026
Fortunately, we can choose from 5 active drugs outside of the NRTI class: boosted darunavir (only 2 primary mutations, 33f, 84v), maraviroc, raltegravir, and etravirine. While Fuzeon would also be effective, I would not use an injectable since we have more convenient oral options. This seems like an ideal situation for maraviroc since the virus is CCR5 tropic. I would add two other agents–boosted darunavir and etravirine, saving raltegravir as a back up in case of drug side effect, like etravirine rash.
What I’ve done with similar patients in my practice was to put them on:
1. etravirine
2. maraviroc
3. raltegravir
This adds up to 5 pills twice a day. The patient’s virus(es) has not been exposed to any of these drugs and you do not need to use a PI/r. This has worked great for my patients!